Similar articles for PMID: 27123291

Year	Number of Results
2003	1
2005	1
2007	2
2008	3
2011	3
2012	4
2013	4
2014	7
2015	11
2016	19
2017	16
2018	12
2019	8
2020	7
2021	5
2022	4
2023	2
2024	0

1

Bevacizumab treatment for newly diagnosed glioblastoma: Systematic review and meta-analysis of clinical trials.

Fu P, He YS, Huang Q, Ding T, Cen YC, Zhao HY, Wei X. Fu P, et al. Mol Clin Oncol. 2016 May;4(5):833-838. doi: 10.3892/mco.2016.816. Epub 2016 Mar 10. Mol Clin Oncol. 2016. PMID: 27123291 Free PMC article.

2

Antiangiogenic therapy for high-grade glioma.

Khasraw M, Ameratunga MS, Grant R, Wheeler H, Pavlakis N. Khasraw M, et al. Cochrane Database Syst Rev. 2014 Sep 22;(9):CD008218. doi: 10.1002/14651858.CD008218.pub3. Cochrane Database Syst Rev. 2014. PMID: 25242542 Updated. Review.

3

The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.

Garside R, Pitt M, Anderson R, Rogers G, Dyer M, Mealing S, Somerville M, Price A, Stein K. Garside R, et al. Health Technol Assess. 2007 Nov;11(45):iii-iv, ix-221. doi: 10.3310/hta11450. Health Technol Assess. 2007. PMID: 17999840 Free article. Review.

4

Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years.

Ohno M, Miyakita Y, Takahashi M, Igaki H, Matsushita Y, Ichimura K, Narita Y. Ohno M, et al. Radiat Oncol. 2019 Nov 12;14(1):200. doi: 10.1186/s13014-019-1389-7. Radiat Oncol. 2019. PMID: 31718669 Free PMC article.

5

A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent Glioblastoma.

Brandes AA, Gil-Gil M, Saran F, Carpentier AF, Nowak AK, Mason W, Zagonel V, Dubois F, Finocchiaro G, Fountzilas G, Cernea DM, Chinot O, Anghel R, Ghiringhelli F, Beauchesne P, Lombardi G, Franceschi E, Makrutzki M, Mpofu C, Urban HJ, Pichler J. Brandes AA, et al. Oncologist. 2019 Apr;24(4):521-528. doi: 10.1634/theoncologist.2018-0290. Epub 2018 Sep 28. Oncologist. 2019. PMID: 30266892 Free PMC article. Clinical Trial.

6

Gliadel wafer implantation combined with standard radiotherapy and concurrent followed by adjuvant temozolomide for treatment of newly diagnosed high-grade glioma: a systematic literature review.

Ashby LS, Smith KA, Stea B. Ashby LS, et al. World J Surg Oncol. 2016 Aug 24;14(1):225. doi: 10.1186/s12957-016-0975-5. World J Surg Oncol. 2016. PMID: 27557526 Free PMC article. Review.

7

Phase II, Open-Label, Randomized, Multicenter Trial (HERBY) of Bevacizumab in Pediatric Patients With Newly Diagnosed High-Grade Glioma.

Grill J, Massimino M, Bouffet E, Azizi AA, McCowage G, Cañete A, Saran F, Le Deley MC, Varlet P, Morgan PS, Jaspan T, Jones C, Giangaspero F, Smith H, Garcia J, Elze MC, Rousseau RF, Abrey L, Hargrave D, Vassal G. Grill J, et al. J Clin Oncol. 2018 Apr 1;36(10):951-958. doi: 10.1200/JCO.2017.76.0611. Epub 2018 Feb 7. J Clin Oncol. 2018. PMID: 29412784 Clinical Trial.

8

Progression-Free but No Overall Survival Benefit for Adult Patients with Bevacizumab Therapy for the Treatment of Newly Diagnosed Glioblastoma: A Systematic Review and Meta-Analysis.

Kaka N, Hafazalla K, Samawi H, Simpkin A, Perry J, Sahgal A, Das S. Kaka N, et al. Cancers (Basel). 2019 Nov 4;11(11):1723. doi: 10.3390/cancers11111723. Cancers (Basel). 2019. PMID: 31689995 Free PMC article. Review.

9

Hypofractionated-intensity modulated radiotherapy (hypo-IMRT) and temozolomide (TMZ) with or without bevacizumab (BEV) for newly diagnosed glioblastoma multiforme (GBM): a comparison of two prospective phase II trials.

Carlson JA, Reddy K, Gaspar LE, Ney D, Kavanagh BD, Damek D, Lillehei K, Chen C. Carlson JA, et al. J Neurooncol. 2015 Jun;123(2):251-7. doi: 10.1007/s11060-015-1791-4. Epub 2015 Apr 29. J Neurooncol. 2015. PMID: 25920710 Clinical Trial.

10

Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: the randomized, open-label, phase II ARTE trial.

Wirsching HG, Tabatabai G, Roelcke U, Hottinger AF, Jörger F, Schmid A, Plasswilm L, Schrimpf D, Mancao C, Capper D, Conen K, Hundsberger T, Caparrotti F, von Moos R, Riklin C, Felsberg J, Roth P, Jones DTW, Pfister S, Rushing EJ, Abrey L, Reifenberger G, Held L, von Deimling A, Ochsenbein A, Weller M. Wirsching HG, et al. Ann Oncol. 2018 Jun 1;29(6):1423-1430. doi: 10.1093/annonc/mdy120. Ann Oncol. 2018. PMID: 29648580 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

94 results

Results by year